 NCI Activated as Clinical Site for Phase 1b2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic Cancer MIRAMAR, Fla., Dec. 08, 2022 GLOBE NEWSWIRE HCW Biologics Inc. the Company or HCW Biologics NASDAQ: HCWB, a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation ... The post HCW Biologics Enters CRADA with National Cancer Institute appeared first on ForexTV... 